David Thomson - 15 Jul 2026 Form 4 Insider Report for MANNKIND CORP (MNKD)

Reporting relationship: EVP Genl Counsel & Secretary
Issuer ticker: MNKD
Reported as of: 15 Jul 2026
Net transaction value: -$97,641
SEC form: 4
Accepted by SEC: 17 Jul 2026, 21:43:38 UTC
Prior SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ David Thomson

Key filing fact

David Thomson filed Form 4 for MANNKIND CORP (MNKD) on 17 Jul 2026.

Key facts

This page summarizes David Thomson's Form 4 filing for MANNKIND CORP (MNKD).
7 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 21:43.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: -$97,641.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001297976 Primary reporting owner

Thomson David

Relationship: EVP Genl Counsel & Secretary
Address: 1 CASPER STREET, DANBURY
Signature: /s/ David Thomson
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNKD transaction

Common Stock, $0.01 Par Value

Options Exercise

Transaction value
Shares: +93,790
Change %: +11%
Price: $0.000000^*
Shares after: 920,089
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F1

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value
Shares: -51,632
Change %: -5.6%
Price: $4.09^*
Shares after: 868,457
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value
Shares: -12,662
Change %: -1.5%
Price: $4.09^*
Shares after: 855,795
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value
Shares: -17,754
Change %: -2.1%
Price: $4.09^*
Shares after: 838,041
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value
Shares: -16,378
Change %: -2%
Price: $4.09^*
Shares after: 821,663
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Sale

Transaction value: $97,641
Shares: -24,109
Change %: -2.9%
Price: $4.05
Shares after: 797,554
Date: 17 Jul 2026
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNKD transaction Derivative

Performance Restricted Stock Unit

Options Exercise

Transaction value
Shares: -93,790
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock, $0.01 Par Value
Underlying amount: 93,790
Exercise price
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

Footnote F2

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

Footnote F3

Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

Footnote F4

The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F5

Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.